Missing eMAR/eTAR Documentation for Medications and Monitoring
Summary
The facility failed to ensure that residents’ electronic medication administration records (eMARs) and electronic treatment administration records (eTARs) were accurately documented for four residents. The deficiency was identified through interview and record review and involved missing documentation for medications, treatments, and monitoring tasks that were ordered for multiple days. The facility policy titled Medication Administration stated that medications are to be documented as each medication is prepared on the MAR. For one resident with diagnoses including peripheral vascular disease and depression, the 02/2026 eMAR showed no documentation on multiple dates for several scheduled medications and treatments, including Benadryl Allergy, Lexapro, amoxicillin-pot clavulanate, Coreg, Eliquis, Procardia XL, Pro-Stat, smoking checks, pain scale documentation, enhanced barrier precautions, abdominal binder use, and monitoring for tardive dyskinesia, target behaviors, and active bleeding/bruising related to anticoagulant therapy. The record review also found no progress note documentation or evidence of refusals for those missed entries. For another resident with diagnoses including type 2 diabetes mellitus with diabetic neuropathy, the 03/2026 eMAR/eTAR lacked documentation for numerous medications and monitoring orders, including atorvastatin, B12 folate, duloxetine, ferrous sulfate, melatonin, metoprolol, nifedipine ER, renal vitamin, trazodone, vitamin C, Vraylar, Zyrtec, clonazepam, famotidine, gabapentin, midodrine, amino acids, calcium acetate, tizanidine, dialysis thrill and bruit checks, blood pressure and pulse monitoring, pain scale documentation, weekly skin assessment, and multiple other ordered observations such as edema, odor, urine color, opioid overdose monitoring, psychotropic side effects, and substance abuse impairment checks. The resident’s progress notes also did not show refusals or other documentation for the missing entries. For the remaining two residents, record review showed repeated missing eMAR documentation for scheduled medications and treatments across March 2026. One resident with chronic atrial fibrillation, paranoid schizophrenia, dementia, depression, and hypertension had missing documentation for multiple medications including amiodarone, atorvastatin, cholecalciferol, donepezil, ferrous sulfate, fish oil, Lasix, metoprolol, quetiapine, trazodone, Xarelto, methadone, Colace, divalproex, famotidine, memantine, and several monitoring and care tasks such as pain scale checks, smoking checks, hourly elopement-risk monitoring, bleeding/bruising monitoring, edema checks, tardive dyskinesia monitoring, and observation for psychotropic side effects. Another resident with diabetes, depression, anxiety, COPD, and venous insufficiency had missing documentation for medications and treatments including duloxetine, Flomax, folic acid, Linzess, methadone, MiraLax, potassium chloride, pravastatin, ascorbic acid, ferrous sulfate, fluticasone, furosemide, insulin aspart, metformin, desmopressin, cyproheptadine, Robaxin, and multiple ordered monitoring and care tasks such as pain scale documentation, enhanced barrier precautions, edema checks, suprapubic catheter care, head-of-bed elevation, pressure-reducing cushion use, and observation for opioid overdose and psychotropic side effects. In interview, the QI nurse stated nurses are expected to chart in real time and acknowledged that if it was not charted in the eMAR/eTAR, it did not happen. The Regional VP stated the nurses should always chart in real time or document refusals and confirmed the missing documentation during record review.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.